NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.54 -1.09 (-1.32%) GOLD FUTURES
2,296.90 -60.80 (-2.58%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,912.42 -2,483.01 (-4.93%)
BCEL Jun 2024 5.000 put
| Previous close | 4.7000 |
| Open | 4.8000 |
| Bid | 4.4000 |
| Ask | 5.1000 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 4.7000 - 4.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireAtreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (Nasdaq: IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up t
- GlobeNewswire
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary supp
ZacksAtreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
